Infinimmune
infinimmune.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$87M
2 rounds on record
Latest round
$75M
Venture round · Aug 2026 · 1 mo ago
Team
51-200
employees, estimated range
Backers
1
Playground
The money's age
Fresh money
1 months since the last round · not hiring
Momentum
35/100
in the news, fresh money
Last sign of life
this month
a posting or a news item
Tractionpublic signals, read monthly
Web presence
top 6%
of 133.2M domains by links, Common Crawl
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Aug 2026 | $75M | — | ventureburn.com |
| Seed | Dec 2022 | $12M | — | businesswire.com |
Backed byfrom the funds' portfolios and accelerator catalogs
Playground Similar startupsby what they do, their industry and backers
Welcome to the first map of human biology. Parallel Bio reimagined the entire drug discovery process from the ground up - creating a system…
NeuroBionics aims to advance neurotech and human health through bioelectronic medicine, by developing devices that seamlessly integrate…
PicnicAI builds intelligence to accelerate human health through PicnicHealth and PicnicResearch. Discover our vision for transforming…
Backing the bold to build iconic companies committed to planetary and human health.
Frontier AI for Human Biology. Click to read NOETIK, a Substack publication with thousands of subscribers.
Optomics® uses photonics and AI to decode human biology for clinical diagnostics, trial stratification, and drug development. Personalized…
News
Infinimmune Raises $75 Million Series A To Advance Human-Derived Antibody Pipeline
Infinimmune has raised $75 million in Series A financing to advance a pipeline of fully human antibody therapeutics for atopic dermatitis and other inflammatory diseases. The round was co-led by Regeneron Ventures and Playground Global, with participation
Read more
Report
Infinimmune Secures $75M for a More Human Approach to Developing Better Antibody Drugs
Immunology startup Infinimmune is developing antibody drugs with potential advantages over traditional monoclonal antibodies. The Series A financing will support two lead programs entering the clinic in atopic dermatitis.
Read more
Report
Press Release Infinimmune Raises 75 Million Series A Financing to Advance Pipeline of Human-Derived Antibodies for Atopic Dermatitis and Inflammatory Disease August 11, 2026 Read More
Read more
Report
Infinimmune Appoints Anthony Slavin, Ph.D., as Senior Vice President of Portfolio Strategy
ALAMEDA, Calif., April 27, 2026--Infinimmune Appoints Anthony Slavin, Ph.D., as Senior Vice President of Portfolio Strategy
Read more
Report
Pro access
Upgrade to see all 10 mentions
Upgrade to a paid plan to read every media mention of this company - funding news, awards, product launches and press releases from all the outlets writing about it.
Every media mention and press release
Funding news, awards and product launches
Fresh coverage from every outlet writing about the company
Upgrade now
Cancel anytime. Secure checkout. Instant activation.